sees qtr-three revenue $num-one million to $num-two million.
reaffirms year-six full year forecast for revenues and profit.
emergent biosolutions - in quarter, inventory write-offs related to raw materials, in-process batches manufactured at bayview facility.
emergent biosolutions - fy other product sales, expected to be impacted on assumption that a new raxibacumab contract to be awarded later than planned.